Vertex Pharmaceuticals (VRTX) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted an opinion for the label expansion of Kaftrio in combination with ivacaftor for the treatment of people with cystic fibrosis aged two years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator gene.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals upgraded to Buy from Hold at Erste Group
- RBC says Journavx review documents hint at focus in future chronic pain data
- Cautious Hold on Vertex Pharmaceuticals Amid Early-Stage Uncertainty of VX-522 Development
- Vertex Pharmaceuticals files automatic mixed securities shelf
- Q4 Earnings Surprise Greenlights CRISPR Therapeutics Stock Climb